BioArctic AB (publ)
STO: BIOA-B.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gunilla Osswald
- Employees
- 107
- Headquarters
- Stockholm, Sweden
- IPO year
- 2017
- Market cap
- SEK 28.1B
- Website
- https://www.bioarctic.se
Loading BIOA-B…
Loading profile data…Frequently asked questions about BIOA-B
What does BioArctic AB (publ) (BIOA-B.ST) do?
BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials...
Where does BIOA-B.ST trade?
BioArctic AB (publ) (BIOA-B.ST) trades on the Stockholm Stock Exchange.
What sector is BIOA-B.ST in?
BioArctic AB (publ) (BIOA-B.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BioArctic AB (publ)?
Gunilla Osswald is the chief executive officer of BioArctic AB (publ) (BIOA-B.ST).
Where is BioArctic AB (publ) headquartered?
BioArctic AB (publ) is headquartered in Sweden.
Does BIOA-B.ST pay a dividend?
Yes — BioArctic AB (publ) (BIOA-B.ST) paid a trailing twelve-month dividend of SEK 2.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did BIOA-B.ST go public?
BioArctic AB (publ) (BIOA-B.ST) completed its initial public offering in 2017.